
AbbVie (ABBV): Growth Momentum vs. Valuation Risk
AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.
Everything tagged "biopharma" across the TickerSpark archives.

AbbVie is delivering strong growth from Skyrizi, Rinvoq and neuroscience, but a rich valuation and heavy debt keep the stock in Hold territory.

United Therapeutics combines a cash-rich balance sheet with record Tyvaso sales and multiple late-stage catalysts, but concentration in its flagship franchise keeps execution risk elevated. The stock looks fairly valued for a high-quality specialty biopharma with meaningful upside tied to 2027 regulatory decisions.

Corcept is evolving from a single-product endocrinology story into a two-franchise biopharma company, with Lifyorli adding a new growth engine. The stock looks fairly valued after strong Q2 revenue growth, but execution risk and a young launch keep the rating at Hold.

AstraZeneca’s oncology and respiratory franchises are offsetting legacy erosion, supporting a Buy rating despite leverage and trial risk. The stock looks reasonably valued with multiple late-stage catalysts still ahead.

Novo Nordisk still pairs elite profitability with strong obesity growth, but U.S. pricing pressure is tempering the once-clean hypergrowth story. The Wegovy pill and broader cardiometabolic pipeline keep the long-term case intact.

Sanofi is becoming a more focused biopharma compounder, led by Dupixent growth, vaccine strength, and expanding launch sales. The stock looks inexpensive versus its cash generation and earnings power.

GSK is evolving from a mature pharma cash generator into a more balanced growth story, with Specialty Medicines driving faster growth and margins improving. The stock still looks reasonably valued versus its earnings power and pipeline.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime